DNMT3A r882 mutations predict a poor prognosis in AML a meta-analysis from 4474 patients

Medicine (United States)

Volumn 95, Issue 18, 2016, Pages e3519-

  Yuan, Xiao Qing ^a   Peng, Li ^b   Zeng, Wen Jing ^a   Jiang, Bin Yuan ^b   Li, Guan Cheng ^b   Chen, Xiao Ping ^a,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA METHYLTRANSFERASE 3A; DNA (CYTOSINE 5) METHYLTRANSFERASE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOGENETICS; DNA METHYLATION; GENE MUTATION; HUMAN; LEUKEMOGENESIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL PREDICTION; SYSTEMATIC REVIEW; GENETICS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; SURVIVAL ANALYSIS;

DNA (CYTOSINE-5-)-METHYLTRANSFERASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84969753248     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003519     Document Type: Review

References (40)

1. Kato T, Sakata-Yanagimoto M, Nishikii H, et al. Hes1 suppresses acute myeloid leukemia development through FLT3 repression. Leukemia. 2015;29:576-585.
2. Ignatz-Hoover JJ, Wang H, Moreton SA, et al. The role of TLR8 signaling in acute myeloid leukemia differentiation. Leukemia. 2015;29:918-926.
3. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109:431-448.
4. Niederwieser C, Kohlschmidt J, Volinia S, et al. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2015;29:567-575.
5. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136-1152.
6. Yan P, Frankhouser D, Murphy M, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012;120:2466-2474.
7. Marcucci G, Yan P, Maharry K, et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol. 2014;32:548-556.
8. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909-1918.
9. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079-1089.
10. Chen BF, Chan WY. The de novo DNA methyltransferase DNMT3A in development and cancer. Epigenetics. 2014;9:669-677.
11. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43:309-315.
12. Hahn CN, Ross DM, Feng J, et al. A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia. 2015;29:2101-2104.
13. Liang DC, Liu HC, Yang CP, et al. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A. Blood. 2013;121:2988-2995.
14. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424-2433.
15. Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29:2889-2896.
16. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793-795.
17. Chun M. Precision medicine initiative in the offing. Cancer Discov. 2015;5:456.
18. Mayle A, Yang L, Rodriguez B, et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood. 2015;125:629-638.
19. Kim SJ, Zhao H, Hardikar S, et al. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood. 2013;122:4086-4089.
20. Russler-Germain DA, Spencer DH, Young MA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wildtype DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25:442-454.
21. Lin J, Yao DM, Qian J, et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One. 2011;6:e26906.
22. Im AP, Sehgal AR, Carroll MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014;28:1774-1783.
23. Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012;26:1247-1254.
24. Gaidzik VI, Schlenk RF, Paschka P, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013;121:4769-4777.
25. Park SH, Choi JC, Kim SY, et al. Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients. Biomed Res Int. 2015;2015:723682.
26. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
27. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
28. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Ottawa Hospital Research Institute, 2013, Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed 2013 Jun 23
29. Tie R, Zhang T, Fu H, et al. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. PLoS One. 2014;9:e93353.
30. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894-1907.
31. Gangatharan SA, Grove CS, P'ng S, et al. Acute myeloid leukaemia in Western Australia 1991-2005: a retrospective population-based study of 898 patients regarDing epidemiology, cytogenetics, treatment and outcome. Intern Med J. 2013;43:903-911.
32. Deplus R, Denis H, Putmans P, et al. Citrullination of DNMT3A by PADI4 regulates its stability and controls DNA methylation. Nucleic Acids Res. 2014;42:8285-8296.
33. Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15:152-165.
34. Li Y, Zhu B. Acute myeloid leukemia with DNMT3A mutations. Leuk Lymphoma. 2014;55:2002-2012.
35. Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30:742-750.
36. Gale RE, Lamb K, Allen C, et al. Simpson's paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33:2072-2083.
37. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 2012;119:5824-5831.
38. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381:484-495.
39. Singh H, Asali S, Werner LL, et al. Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leuk Res. 2011;35:1611-1615.
40. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.